%0 Journal Article %T Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Yue-Yun, Chen %A Ye, Hong %A Yang, Fu %A Qing, Li %A Pan-Pan, Lin %A Zhen-Yu, Ding %D 2019 %\ 08/01/2019 %V 20 %N 8 %P 2415-2420 %! Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours %K NSCLC %K EGFR-TKI %K sequential administration %K Pemetrexed %K PFS %R 10.31557/APJCP.2019.20.8.2415 %X Objectives: The optimal combination of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors(TKIs) and chemotherapy has helped to improve therapeutic effects in non-small-cell lung cancer (NSCLC). This studyaimed to explore the progression free survival (PFS) of patients after sequential administration of TKI and pemetrexedchemotherapy. Methods: This study retrospectively screened treatment-naive advanced NSCLC patients harbouringEGFR mutations who were prescribed a TKI and salvaged with pemetrexed chemotherapy or vice versa. The total,initial and salvage PFS were collected. Results: The total PFS including both the initial and salvage PFS was 18.0 mon(95% CI: 14.1–21.9 mon), which was not influenced by the sequence of administration (TKI first: 18.0 mon, 95% CI:15.8–20.2 mon, pemetrexed first: 16.1 mon, 95% CI: 9.1–23.1 mon, HR 0.92, P=0.748). A longer PFS was achievedfor TKI over chemotherapy in both the initial (10.6 and 5.9 mon, HR 2.62, P=0.001) and salvage therapy (12.0 and 6.0mon, HR 1.29, P=0.001). TKI remained effective either before (10.6 mon) or after (12.0 mon) chemotherapy (HR 0.96,P=0.853). The same trend was observed for chemotherapy (5.9 and 6.0 mon for initial and salvage therapy, respectively,HR 0.82, P=0.417). Conclusions: The sequential administration of TKI and pemetrexed chemotherapy achieved a longPFS and was a suitable treatment for advanced NSCLC. %U https://journal.waocp.org/article_88707_d2d8e0dc5110c93f601bbcaa0c9fddb3.pdf